HK Stock MarketDetailed Quotes
02268 WUXI XDC
- 19.060
- +0.120+0.63%
Market Closed May 10 16:08 CST
22.83BMarket Cap73.03P/E (TTM)
19.240High18.300Low4.34MVolume19.100Open18.940Pre Close81.64MTurnover0.36%Turnover Ratio73.03P/E (Static)1.20BShares34.00052wk High3.79P/B22.83BFloat Cap12.08052wk Low--Dividend TTM1.20BShs Float34.000Historical High--Dividend LFY4.96%Amplitude12.080Historical Low18.824Avg Price500Lot Size--Div YieldTTM--Div Yield LFY
About WUXI XDC Company
Pharmaceutics Federation is a leading contract research, development and production organization (CRDMO), focusing on the global ADC and broader bioconjugate market, and is a leading CRDMO providing integrated end-to-end services. Services are provided by nearby state-of-the-art laboratories and manufacturing facilities, significantly reducing development time and costs. Our more than 1,000 skilled employees spread across a global network provide expert-oriented, high-quality and successful project execution for our clients. Helping our biopharmaceutical partners accelerate the development of innovative therapies for the benefit of patients globally by providing the most comprehensive single-source, open-access platform of pharmacology capabilities and technology.
Company Profile
Symbol02268
Company NameWUXI XDC
ISINKYG9808A1058
Listing DateNov 17, 2023
Issue Price20.60
Shares Offered178.45M share(s)
FoundedDec 14, 2020
Registered AddressCayman Islands
Chairmanzhisheng chen
Secretaryxiaojie xi
Audit InstitutionDeloitte & Touche Tohmatsu Certified Public Accountants
Company CategoryOther
Registered OfficePO Box 309, Ugland House Grand Cayman KY1-1104 Cayman Islands
Head Office and Principal Place of Business31st Floor, Times Square Tower 2, 1 Matheson Street, Causeway Bay, Hong Kong
Fiscal Year Ends12-31
Employees1178
MarketHong Kong motherboard
EmailWuxixdc.ir@wuxibiologics.com
Websitehttp://www.wuxixdc.com
Business Wu Xi XDC Cayman Inc is a holding company mainly engaged in providing contract research, development and production services (CRDMO) for antibody-coupled drugs (ADCs) and a wider range of bioconjugated drugs (CRDMO). The company conducts its business through two divisions. The Research Services Division, which is based on paid service standards, provides research services to clients through paid service contracts. The Research Services Division, which provides a full-time equivalent benchmark, provides a task force whose staff is dedicated to customer research for a specific period of time. Based on biopharmaceuticals and small molecule drugs, the company also provides comprehensive services across fields, covering the discovery, process development, and production of pharmaceutical production quality management (GMP) production of bioconjugated drugs, connectors and payloads. The company conducts its business in domestic and foreign markets.
Company Executives
- Name
- Position
- Salary
- jincai li
- CEOs，Executive Director，Chairman of the Strategy Committee
- --
- jingwei zhang
- Executive Director，Chief Operating Officer，Authorized Representative
- --
- xiaojie xi
- Executive Director，chief financial officer，Authorized Representative，Company Secretary
- --
- zhisheng chen
- Chairman of the Board，Non-executive directors，Chairman of the Nomination Committee，Strategy Committee Members
- --
- weichang zhou
- Non-executive directors，Strategy Committee Members
- --
- ming shi
- Non-executive directors，Remuneration Committee Members
- --
- Ulf Grawunder
- Independent Non-Executive Director，Remuneration Committee Chairman，Strategy Committee Members，Audit Committee Members，Nomination Committee Members
- --
- Stewart John Hen
- Independent Non-Executive Director，Audit Committee Members，Strategy Committee Members，Remuneration Committee Members
- --
- hao zhou
- Independent Non-Executive Director，Chairman of the Audit Committee，Nomination Committee Members
- --
- meiying zhu
- chief technology officer
- --
- jianjun luo
- VP
- --
Analysis
Price Target
No Data
Heat List
HK
Overall
Symbol
Latest Price
%Chg